Trials / No Longer Available
No Longer AvailableNCT02433314
An Open Label, Expanded Access Protocol With SAGE-547 for Super-Refractory Status Epilepticus
An Open Label, Expanded Access Protocol to Evaluate the Efficacy and Safety of SAGE-547 Injection in the Treatment of Subjects With Super-Refractory Status Epilepticus
- Status
- No Longer Available
- Phase
- —
- Study type
- Expanded Access
- Enrollment
- —
- Sponsor
- Supernus Pharmaceuticals, Inc. · Industry
- Sex
- All
- Age
- 6 Months
- Healthy volunteers
- —
Summary
This is an open-label, expanded access protocol, designed to offer treatment with SAGE-547 to subjects in SRSE, and to evaluate the efficacy and safety of SAGE-547 administered as a continuous intravenous infusion to these subjects
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | SAGE-547 |
Timeline
- First posted
- 2015-05-04
- Last updated
- 2025-09-15
Source: ClinicalTrials.gov record NCT02433314. Inclusion in this directory is not an endorsement.